Tue, May 6, 8:07 PM (11 days ago)
**Summary of Day One Biopharmaceuticals, Inc. (DAWN: Nasdaq Global Select Market)** **Financial Health & Performance Metrics (Q1 2025):** - **Revenue:** $30.8 million (product revenue: $30.5M, license revenue: $0.3M) - **Net Loss:** $36.0 million - **Gross Margin:** -11.3% (cost of product revenue: $2.9M) - **Operating Expenses:** $71.8 million (R&D: $39.6M, SG&A: $29.3M) - **Net Margin:** -117.4% - **Cash Flow:** -$91.6 million (operating: -$59.0M, investing: -$32.6M) **Earnings Changes (Q1 2025 vs. Q1 2024):** - **Revenue Growth:** +100% (product: +100%, license: +100%) - **Net Loss Decrease:** 42.3% ($26.4M) - **Operating Expenses Increase:** 7.6% ($5.1M) - **R&D Expenses Decrease:** 1.5% ($0.6M) - **SG&A Expenses Increase:** 10.4% ($2.8M) **Quarterly Performance Discussion:** - **Revenue:** Driven by product sales of OJEMDA ($30.5M) and license revenue ($0.3M). - **Expenses:** R&D expenses decreased slightly due to lower license-related payments. SG&A expenses increased due to headcount growth and commercial launch activities. - **Cash Flow:** Negative cash flow due to operating losses and investing activities. **Trends & Uncertainties:** - **Revenue Growth:** Positive trend due to OJEMDA sales and license revenue. - **Expense Management:** Need to control SG&A expenses to improve profitability. - **Cash Flow:** Negative trend due to operating losses and investing activities. **Future Operations Impact:** - **Revenue:** Continued growth expected from OJEMDA sales and potential new products. - **Expenses:** Need to manage R&D and SG&A expenses to improve profitability. - **Cash Flow:** Need to improve operating performance to generate positive cash flow. **Amendment Summary (if applicable):** - *Not applicable for this summary.* **Note:** Amounts are in thousands, 000s.